What Causes Elevated Lipoprotein(a) Levels in Familial Hypercholesterolemia?
Elevated lipoprotein(a) levels was not found to be caused by FH, but may help with clinical recognition of genetic FH.
Familial Hypercholesterolemia
Combination Therapy of Bempedoic Acid, Ezetimibe Now Available as Adjunct to Statins
Nexlizet (bempedoic acid and ezetimibe; Esperion) is now available for use as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
National Lipid Association Statement on Genetic Testing in Dyslipidemia
A scientific statement from the National Lipid Association outlines the implications of genetic testing in patients with dyslipidemia.
Familial Hypercholesterolemia Associated With Increased Mortality Risk After Acute Myocardial Infarction
Patients with familial hypercholesterolemia were found to be at increased risk for long-term mortality and cardiovascular events after acute myocardial infarction.
Patients With Familial Hypercholesterolemia at Higher Risk for Cardiac Complications From COVID-19
Individuals with novel coronavirus disease 2019 who have familial hypercholesterolemia may be at higher risk for cardiac complications and atherosclerotic cardiovascular disease in the long-term.
Bempedoic Acid Now Available as First-in-Class LDL-C Lowering Therapy
Bempedoic acid is a first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers LDL-C by inhibiting cholesterol synthesis in the liver.
Reviewing Evidence on the Screening, Diagnosis, and Care of Familial Hypercholesterolemia
Familial hypercholesterolemia is one of the most clinically relevant monogenic disorders contributing to the development of atherosclerotic cardiovascular disease.
Evolocumab Found Effective in Reducing Plasma LDL-C in Familial Hypercholesterolemia
Treatment with evolocumab was found to be effective in reducing plasma levels of low-density lipoprotein cholesterol in familial hypercholesterolemia.
FDA Approves Bempedoic Acid, Ezetimibe Combination Therapy for LDL-C Lowering
Nexlizet will be available as 180mg bempedoic acid/10mg ezetimibe tablets in 30- and 90-count bottles in July 2020; Nexletol will be available on March 30, 2020.
Effects of Hypertriglyceridemia on Lipoprotein Function in Familial Combined Hyperlipidemia
Patients with familial combined hyperlipidemia may have more severe pro-atherogenic changes in the presence vs absence of hypertriglyceridemia.
-
Loading...
-
Loading...
Next post in Cardiovascular and Metabolic Disorders
